What is the role of poly ADP ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer?

Updated: Dec 06, 2018
  • Author: Shannon M Grabosch, MD; Chief Editor: from Memorial Sloan-Kettering - Yukio Sonoda, MD  more...
  • Print
Answer

Answer

PARP inhibitors are FDA approved as maintenance treatment in a platinum-sensitive relapse in patients who have had at least a partial platinum response.

Olaparib (Lynparza) 400 mg PO BID continuously may be used as monotherapy for advanced ovarian cancer with deleterious or suspected deleterious germline BRCA mutations (as detected by an FDA-approved test, BRACAnalysis CDxTM) in patients who have been treated with three or more prior lines of chemotherapy. [46]

Olaparib 300 mg (tablet) PO BID continuously may be used for maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. It is active both in patients with and those without BRCA mutations. [47, 48]

Rucaparib (Rubraca) 600 mg PO BID continuously is indicated for monotherapy of women with deleterious BRCA mutations (germline and/or somatic) associated with advanced ovarian cancer who have been treated with two or more prior lines of chemotherapy. [49] This agent is also indicated for maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy. [50, 49]

Niraparib (Zejula) 300 mg PO daily is approved for maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in women who have had complete or partial response to platinum-based chemotherapy independent of BRCA status. [51]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!